Marty Makary resigns as FDA commissioner

The FDA just lost its commissioner again — and that matters because this is the agency that decides what medicines, vaccines, vapes, and food additives Americans get. Marty Makary is resigning on Tuesday, May 12, after a little more than a year in the job, and Kyle Diamantas is expected to take over in an acting role. The immediate story is personnel. But the real story is that the FDA has been operating under constant political cross-pressure, and Makary ended up squeezed from almost every side. ### Did he really resign? Yes. Multiple outlets reported on May 12 that Makary was stepping down that day after roughly 13 months leading the agency, and Reuters matched the core details — including that Diamantas would serve in an acting capacity. So this is not just a social-media rumor. ### Was this about “Big Food”? Not in the simple way that social posts are framing it. Makary did make food policy a visible part of his tenure — especially the push to phase out synthetic food dyes and the broader “Make America Healthy Again” turn in federal nutrition policy. (politico.com) But the reporting around his exit points much more strongly to a pileup of conflicts: abortion-pill politics, vape approvals, drug-review disputes, staff turmoil, and frustration inside the Trump administration. Food fights were part of the atmosphere, not the clear single cause. ### So what actually pushed him out? Basically, he ran out of allies. Anti-abortion groups were angry that the FDA had not moved faster against telehealth prescribing of mifepristone. Vaping companies and their allies complained that Makary was blocking flavored products they saw as crucial. Biopharma companies were also frustrated by what they viewed as inconsistent reviews and high-profile rejections. On top of that, Politico reported that HHS Secretary Robert F. Kennedy Jr. made the call, with White House signoff. (abcnews.com) ### Why was the FDA so unstable under him? Because the agency was already in churn, and Makary never really got control of it. Reports describe mass layoffs, turnover among senior leaders, low morale, and repeated fights over whether science staff or political appointees were really steering decisions. The FDA always sits between science and politics. But under Makary, that balance looked especially shaky. (politico.com) ### What about the food-dye crackdown? That episode helps explain the style of this FDA. Makary publicly announced a big move against petroleum-based food dyes. But more than a year later, the detailed rulemaking and scientific paperwork still had not fully materialized, and much of the effort depended on voluntary industry pledges. That gap — big announcement first, regulatory scaffolding later — became a broader criticism of the agency’s approach. (pbs.org) ### Why does Diamantas matter? Because he comes from the food side of the FDA, not just the drug side, and that signals where the administration may want continuity. If he takes over as acting commissioner, the agency gets a caretaker who is already inside the current policy orbit rather than a reset figure from outside. That suggests more short-term continuity than cleanup. That last part is an inference, but it fits the personnel move. (ksat.com) ### What’s the real takeaway? Makary’s resignation looks less like one clean scandal and more like a regulator collapsing under too many political demands at once. The FDA is supposed to be boring in the best way — steady, procedural, science-heavy. Instead, it has become another front in the administration’s internal fights. That is the part that should worry anyone who cares about how health rules get made. (pbs.org) (politico.com)